C Adem

Summary

Country: France

Publications

  1. ncbi Microsatellite instability in hereditary and sporadic breast cancers
    Camilo Adem
    1Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Cancer 107:580-2. 2003
  2. ncbi Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature
    C Adem
    Department of Anatomic Pathology, Pitie Salpetriere Hospital, Paris, France
    Br J Cancer 91:237-41. 2004
  3. ncbi ETV6 rearrangements in patients with infantile fibrosarcomas and congenital mesoblastic nephromas by fluorescence in situ hybridization
    C Adem
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mod Pathol 14:1246-51. 2001
  4. ncbi Wide spectrum screening keratin as a marker of metaplastic spindle cell carcinoma of the breast: an immunohistochemical study of 24 patients
    C Adem
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Histopathology 40:556-62. 2002
  5. ncbi Metastatic angiosarcoma masquerading as diffuse pulmonary hemorrhage: clinicopathologic analysis of 7 new patients
    C Adem
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Pathol Lab Med 125:1562-5. 2001
  6. ncbi TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors
    Colleen S Sinclair
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 62:3587-91. 2002
  7. ncbi Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers
    Camilo Adem
    Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 97:1-11. 2003
  8. ncbi ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers
    Camilo Adem
    Division of Laboratory Genetics, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Genes Chromosomes Cancer 41:1-11. 2004
  9. ncbi High-risk lesions in high-risk women: a high-risk formalin-based biology!
    Camilo Adem
    J Clin Oncol 22:1159-61; author reply 1161-2. 2004

Collaborators

Detail Information

Publications9

  1. ncbi Microsatellite instability in hereditary and sporadic breast cancers
    Camilo Adem
    1Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Cancer 107:580-2. 2003
    ..Mismatch repair gene mutations may be secondary random events in breast cancer progression...
  2. ncbi Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature
    C Adem
    Department of Anatomic Pathology, Pitie Salpetriere Hospital, Paris, France
    Br J Cancer 91:237-41. 2004
    ..3 per 1 cm increase; 95% CI, 1.02-1.7; P=0.036). There was no significant difference in OS or CSS between low- and high-grade lesions. In this series, tumour size was a more valuable prognostic factor than tumour grade...
  3. ncbi ETV6 rearrangements in patients with infantile fibrosarcomas and congenital mesoblastic nephromas by fluorescence in situ hybridization
    C Adem
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mod Pathol 14:1246-51. 2001
    ..We confirmed that IFS and the cellular type of CMN are cytogenetically related and can occur synchronously in the same organ...
  4. ncbi Wide spectrum screening keratin as a marker of metaplastic spindle cell carcinoma of the breast: an immunohistochemical study of 24 patients
    C Adem
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Histopathology 40:556-62. 2002
    ..CONCLUSIONS: Wide spectrum screening keratin may be the most useful and convenient antibody in differentiating metaplastic spindle cell carcinoma from other spindle cell lesions in the breast...
  5. ncbi Metastatic angiosarcoma masquerading as diffuse pulmonary hemorrhage: clinicopathologic analysis of 7 new patients
    C Adem
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Pathol Lab Med 125:1562-5. 2001
    ..CONCLUSION: Angiosarcoma should be included in the differential diagnosis of diffuse pulmonary hemorrhage, especially in young adults...
  6. ncbi TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors
    Colleen S Sinclair
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 62:3587-91. 2002
    ..TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors...
  7. ncbi Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers
    Camilo Adem
    Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 97:1-11. 2003
    ..This increased progression rate should be taken into account when considering the surveillance of asymptomatic women...
  8. ncbi ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers
    Camilo Adem
    Division of Laboratory Genetics, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Genes Chromosomes Cancer 41:1-11. 2004
    ....
  9. ncbi High-risk lesions in high-risk women: a high-risk formalin-based biology!
    Camilo Adem
    J Clin Oncol 22:1159-61; author reply 1161-2. 2004